Cargando…
Nivolumab-Induced Bullous Pemphigoid Managed without Drug Withdrawal
The widespread use of anti-programmed cell death receptor-1 (PD-1) agents has shed light to unusual immune-related adverse effects, especially affecting the skin. We report a case of bullous pemphigoid secondary to nivolumab therapy for metastatic renal carcinoma with a previously unreported complet...
Autores principales: | Munera-Campos, Mónica, Plana-Pla, Adrià, Rivera, Noelia, Boada, Aram, Ferrándiz, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292470/ https://www.ncbi.nlm.nih.gov/pubmed/32565564 http://dx.doi.org/10.4103/ijd.IJD_321_18 |
Ejemplares similares
-
Development of bullous pemphigoid during nivolumab therapy
por: Damsky, William, et al.
Publicado: (2016) -
Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023) -
A Case of Bullous Pemphigoid Associated With Nivolumab Therapy
por: Gotera, Nico, et al.
Publicado: (2022) -
Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab
por: Maya, Yuka, et al.
Publicado: (2020) -
Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019)